Gyne-Lotrimin

Gyne-Lotrimin

 [gi″nĕ-lo´trĭ-min]
trademark for a preparation of clotrimazole, an antifungal agent.
References in periodicals archive ?
Fleet 9.5% 53,889 22,968 Massengill GlaxoSmithKline 7.5% 42,518 17,802 Monistat 7 Ortho-McNeil 7.1% 40,452 3,605 Monistat 1 Ortho-McNeil 6.2% 35,308 2,369 Vagisil Combe 5.1% 29,131 6,635 Vagistat 1 Bristol-Myers Squibb 4.6% 25,941 2,047 K-Y Ortho-McNeil 4.1% 23,147 6,543 FDS Alberto-Culver 3.6% 20,134 6,299 Gyne-Lotrimin 3 Pfizer 2.9% 16,631 1,480 (*)Private label brands account for 18.4% of dollar sales and 22.3% of unit sales.
Leading brands in the category include Johnson & Johnson's Monistat, Bristol-Myers Squibb Co.'s Vagistat, Bayer Corp.'s Femstat and Mycelex, and Schering-Plough Corp.'s Gyne-Lotrimin.
Other products, such as Monistat and Gyne-Lotrimin, take seven days to work.
Some of these medicines are now available without prescription, such as miconazole (Monistat) and clotrimazole (Gyne-Lotrimin or Mycelex-G), and you may use them when you know you have a yeast infection.
An over-the-counter preparation such as Monistat or Gyne-Lotrimin brings relief for most of these women, and the problem does not recur.
The "report" is a sales pitch for Gyne-Lotrimin, which has "freed women fromneeding a prescription" to treat their vaginal infections.
Among its feminine hygiene products are three-day and seven-day yeast infection treatments that are equivalent to the leading Monistat and Gyne-Lotrimin brands.
Brand $ sales Rank(**) Advil $189.0 4 Sudafed cold products 60.0 48 Benadryl 60.0 49 Motrin IB 54.6 57 Dimetapp 51.0 59 Imodium AD 48.2 64 Aleve(***) 41.5 72 Tavist 40.5 75 Monistat 7 38.6 79 Afrin 36.1 88 Actifed cold 22.6 145 Drixoral 22.1 153 Nuprin 21.0 157 Triaminic 17.7 180 Cortizone 5/10 15.8 207 Gyne-Lotrimin 14.8 214 Motrin 14.4 220 Chlor-Trimaton 12.0 248 Cortaid 11.5 258 (*)Brands introduced since 1984, excluding existing brands adding switched ingredients.
Schering-Plough has rolled out Gyne-Lotrimin 3, a three-day clotrimazole treatment.
"These products offer women quicker access to treatment and greater control," says Doug Petkus, a spokesman for Schering-Plough HealthCare Products, maker of Gyne-Lotrimin. Petkus stresses, however, that "we're marketing to recurring sufferers of yeast infections, not first-time sufferers." who should consult a doctor for an initial diagnosis.
Best-selling feminine antifungals(*) BY DOLLAR SALES Market Dollar sales Brand Manufacturer share (add 000) Monistat Advanced Care 47.8% $114,523 Mycelex-7 Bayer 13.5% 32,340 Femstat-3 Procter & Gamble 11.7% 28,156 Gyne-Lotrimin Schering-Plough 11.6% 27,836 Femizol-7 Lake 0.6% 1,457 Femcare Schering-Plough 0.2% 574 BY UNIT SALES Market Unit sales Brand Manufacturer share (add 000) Monistat Advanced Care 43.0% 8,866 Mycelex-7 Bayer 15.1% 3,121 Gyne-Lotrimin Schering-Plough 11.5% 2,364 Femstat-3 Procter & Gamble 9.7% 2,003 Femizol-7 Lake 0.8% 158 Femcare Schering-Plough 0.3% 61 * For the 52 weeks through August 25, 1996.
Much of the recent excitement in the category has occurred in the anti-fungicidal segment, driven by the over-the-counter arrival of two yeast infection prescriptions, Monistat 7 (Johnson & Johnson's Ortho Pharmaceutical) and Gyne-Lotrimin (Schering-Plough).